再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

未开盘 07-08 16:00:00 EDT

34.94

-0.54

-1.52%

盘后34.94

+0.000.00%

19:06 EDT

最高35.33	最低34.26	成交量47.94万
今开34.56	昨收35.48	日振幅3.02%
总市值38.64亿	流通市值35.79亿	总股本1.11亿
成交额1,670万	换手率0.47%	流通股本1.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":34.94,"timestamp":1752004800000,"preClose":35.48,"halted":0,"volume":479380,"hourTrading":{"tag":"盘后","latestPrice":34.94,"preClose":34.94,"latestTime":"19:06 EDT","volume":35991,"amount":1257514.74,"timestamp":1752015971601},"delay":0,"floatShares":102423831,"shares":110587154,"eps":-2.480033,"marketStatus":"未开盘","change":-0.54,"latestTime":"07-08 16:00:00 EDT","open":34.56,"high":35.33,"low":34.26,"amount":16698398.859119998,"amplitude":0.030158,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.480033,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752048000000},"marketStatusCode":0,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":35.48,"preHourTrading":{"tag":"盘前","latestPrice":35,"preClose":35.48,"latestTime":"09:25 EDT","volume":1749,"amount":61278.78952800001,"timestamp":1751981100050},"postHourTrading":{"tag":"盘后","latestPrice":34.94,"preClose":34.94,"latestTime":"19:06 EDT","volume":35991,"amount":1257514.74,"timestamp":1752015971601},"volumeRatio":0.823818,"impliedVol":0.1889,"impliedVolPercentile":0.044},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2549484805","title":"再鼎医药7月7日成交额为2286.72万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549484805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549484805?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:32","pubTimestamp":1751963534,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，再鼎医药成交额为2286.72万美元，成交额较昨日增加7.76%，当日成交量为64.33万股。再鼎医药于2025年7月7日跌2.53%，报35.48美元，该股过去5个交易日涨2.13%，年初至今涨35.47%，过去60日涨31.07%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708172503a69cdae9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708172503a69cdae9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4531","LU2488822045.USD","BK4585","BK4588","BK4548","BK4139","ZLAB","BK4526"],"gpt_icon":0},{"id":"2549372152","title":"再鼎医药授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2549372152","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549372152?lang=zh_cn&edition=full","pubTime":"2025-07-07 08:18","pubTimestamp":1751847480,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　再鼎医药（09688）发布公告，于2025年7月2日（美国东部时间），公司根据2024年股权激励计划向2名承授人授出可认购合共1.43万股美国存托股份的购股权，向杜莹博士授出涉及合共4.42万股美国存托股份的受限制股份单位，向3名承授人授出涉及合共1.46万股美国存托股份的受限制股份单位，并向杜莹博士授出涉及合共3.65万股美国存托股份的业绩股份单位。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-07-07/doc-infeqytv6516238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK1588","LU2488822045.USD","BK1161","BK4531","09688","BK1574","BK4526","BK4588","ZLAB","BK4585","BK4548"],"gpt_icon":0},{"id":"2548399991","title":"【再鼎医药(09688.HK)授出购股权、受限制股份单位及业绩股份单位】智通财经APP讯，再鼎医药(09688.HK)发","url":"https://stock-news.laohu8.com/highlight/detail?id=2548399991","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548399991?lang=zh_cn&edition=full","pubTime":"2025-07-04 21:18","pubTimestamp":1751635114,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","BK4526","BK4588","BK4548","BK4585","ZLAB","BK1574","09688","BK1161","BK4531","BK4139","BK1588"],"gpt_icon":0},{"id":"2548399946","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2548399946","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548399946?lang=zh_cn&edition=full","pubTime":"2025-07-04 21:18","pubTimestamp":1751635114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年7月2日(美国东部时间)，公司根据2024年股权激励计划向2名承授人授出可认购合共1.43万股美国存托股份的购股权，向杜莹博士授出涉及合共4.42万股美国存托股份的受限制股份单位，向3名承授人授出涉及合共1.46万股美国存托股份的受限制股份单位，并向杜莹博士授出涉及合共3.65万股美国存托股份的业绩股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","BK1588","BK4531","BK4588","LU2488822045.USD","BK1574","BK4548","09688","BK1161","BK4526","ZLAB"],"gpt_icon":0},{"id":"2548187284","title":"再鼎医药7月2日成交额为1500.71万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548187284","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548187284?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:14","pubTimestamp":1751530446,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，再鼎医药成交额为1500.71万美元，成交额较昨日增加2.72%，当日成交量为42.42万股。再鼎医药于2025年7月2日涨0.91%，报35.49美元，该股过去5个交易日跌3.98%，年初至今涨35.51%，过去60日涨11.71%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703165629a4ccf77b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703165629a4ccf77b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4531","BK4548","LU2488822045.USD","ZLAB","BK4139","BK4526","BK4588"],"gpt_icon":0},{"id":"2548236822","title":"【港股生物医药板块震荡走强】港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548236822","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548236822?lang=zh_cn&edition=full","pubTime":"2025-07-03 14:05","pubTimestamp":1751522751,"startTime":"0","endTime":"0","summary":"港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/03140551458806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4588","02257","09926","02696","399441","01477","HSCEI","BK1588","01672","LU0348784397.USD","BK4548","LU1720050803.USD","BK1191","AAPG","LU2488822045.USD","HSTECH","ZLAB","IE00B5MMRT66.SGD","161726","BK4531","IE00B543WZ88.USD","BK1515","YANG","BK4614","07226","BK4585","09688","IE00BPRC5H50.USD","LU1794554557.SGD","BK4139","LU0417516571.SGD","LU0348783233.USD","BK4526","BK1574"],"gpt_icon":0},{"id":"2548822973","title":"港股生物医药板块震荡走强康方生物、圣诺医药、歌礼制药涨超10%亚盛医药涨超7%复宏汉霖、科技药业、再鼎医药涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548822973","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548822973?lang=zh_cn&edition=full","pubTime":"2025-07-03 14:05","pubTimestamp":1751522700,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","IE00B543WZ88.USD","BK4614","02696","161726","BK4526","BK4588","BK1161","HSTECH","IE00B5MMRT66.SGD","BK1191","09926","BK1515","07226","BK1588","YANG","BK4585","01477","BK4139","LU1720050803.USD","BK4531","AAPG","399441","LU0348783233.USD","BK4548","IE00BPRC5H50.USD","ZLAB","LU0348784397.USD","LU0417516571.SGD","01672","LU2488822045.USD","HSCEI","BK1574","LU1794554557.SGD","02257"],"gpt_icon":0},{"id":"2548482694","title":"港股午评：三大指数齐跌 科技股弱势 钢铁股回调 创新药概念股继续强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2548482694","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548482694?lang=zh_cn&edition=full","pubTime":"2025-07-03 12:00","pubTimestamp":1751515239,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"717843a25495c7bc4e8ea290afaa562a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["000898","MIUmain","161726","HSTECH","MCHmain","01810","00700","513600","HSCEI","ZLAB","07226","06181","BABA","ALBmain","01177","06978","03690","03086","09992","159992","01053","00347","02833","399441","KSTmain","HSI","MPNGY","MHImain","TTTN","HSImain","JD","YANG","159938","09688","METmain","09939","01024","01801","02097","159562","TCEHY","08496","09618","09926","HTCD.SI","HHImain","HMTD.SI","TCHmain","02150"],"gpt_icon":0},{"id":"2548554825","title":"【港股异动 | 创新药概念多数走强 政策支持创新药全链条发展 机构称创新药仍为重要投资主线之一】智通财经APP获悉，创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2548554825","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548554825?lang=zh_cn&edition=full","pubTime":"2025-07-03 11:26","pubTimestamp":1751513186,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1888ce0878b381abf8dca3aec6acfa38","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","LU0348783233.USD","BK4531","LU0196878994.USD","LU2328871848.SGD","01801","09926","BK4139","09688","IE00BPRC5H50.USD","BK1588","LU1969619763.USD","BK4548","06978","LU2488822045.USD","06990","BK4526","BK1574","BK1589","06855","159992","AAPG","LU1720050803.USD","LU0417516571.SGD","BK4585","LU0348784397.USD","ZLAB","BK4588","BK1161","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2548406078","title":"【港股异动 | 再鼎医药(09688.HK)涨超4% 宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌III期研究数据取得阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2548406078","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548406078?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:48","pubTimestamp":1751507331,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4526","BK1161","BK4531","BK4548","LU2488822045.USD","BK4139","ZLAB","BK1588","BK4588","BK4585","09688","BK4134","BK1574","III"],"gpt_icon":0},{"id":"2548384098","title":"港股异动 | 再鼎医药(09688)涨超4% 宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌III期研究数据取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2548384098","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548384098?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:48","pubTimestamp":1751507331,"startTime":"0","endTime":"0","summary":"消息面上，据再鼎医药官微消息，6月30日，再鼎医药宣布，评估贝玛妥珠单抗联合化疗作为一线治疗的III期FORTITUDE-101临床研究在预设的中期分析中达到了其主要终点总生存期。贝玛妥珠单抗已获得中国国家药品监督管理局药品审评中心授予的突破性疗法认定，用于治疗FGFR2b阳性胃癌及胃食管结合部癌。此外，一项贝玛妥珠单抗联合化疗及纳武利尤单抗一线治疗胃癌患者的III期研究也正在进行，数据预计在2025年下半年公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","BK4548","BK4585","BK4134","ZLAB","BK4139","BK4588","BK4526","BK4531","LU2488822045.USD","BK1574","III","BK1161","BK1588"],"gpt_icon":0},{"id":"2548862584","title":"再鼎医药7月1日成交额为1460.91万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548862584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548862584?lang=zh_cn&edition=full","pubTime":"2025-07-02 15:59","pubTimestamp":1751443153,"startTime":"0","endTime":"0","summary":"美东时间2025年7月1日，再鼎医药成交额为1460.91万美元，成交额较昨日减少51.08%，当日成交量为41.26万股。再鼎医药于2025年7月1日涨0.57%，报35.17美元，该股过去5个交易日跌6.41%，年初至今涨34.29%，过去60日跌4.14%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702165910a4cacfb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702165910a4cacfb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU2488822045.USD","BK4531","BK4548","BK4585","BK4526","ZLAB","BK4139"],"gpt_icon":0},{"id":"2548005383","title":"再鼎医药盘前涨超4% 贝玛妥珠单抗III期胃癌达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2548005383","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548005383?lang=zh_cn&edition=full","pubTime":"2025-07-01 19:12","pubTimestamp":1751368348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 盘前涨超4%，截至发稿，报36.50美元。消息面上， 中金发布研报称，6月30日，Amgen/再鼎公布Bemarituzumab联合化疗一线治疗FGFR2b阳性胃癌患者III期临床研究中期分析数据，达到了其主要终点总生存期，显示出具有显著统计学意义和临床意义的改善。再鼎拥有该产品大中华区开发和商业化的独家授权。在确保数据安全、合法合规的基础上，探索为创新药研发提供必要的医保数据服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011913329795d1a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507011913329795d1a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4531","BK4526","ZLAB","BK4548","BK4585","III","LU2488822045.USD","BK4134","BK4588","BK4139"],"gpt_icon":0},{"id":"2548071559","title":"【中金：维持再鼎医药(09688.HK)“跑赢行业”评级 目标价34.41港元】智通财经APP获悉，中金发布研报称，维持","url":"https://stock-news.laohu8.com/highlight/detail?id=2548071559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548071559?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:42","pubTimestamp":1751359345,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09688","BK1588","BK4588","BK4585","DCF","BK4531","BK4139","LU2488822045.USD","BK1161","BK1574","BK4548","BK4526","ZLAB"],"gpt_icon":0},{"id":"2548071552","title":"中金：维持再鼎医药(09688)“跑赢行业”评级 目标价34.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548071552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548071552?lang=zh_cn&edition=full","pubTime":"2025-07-01 16:42","pubTimestamp":1751359345,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持再鼎医药2025年和2026年盈利预测不变。维持跑赢行业评级，基于DCF模型，维持H股/US股目标价34.41港元/44.24美元不变，较当前股价有25.4%/27.3%上行空间。Amgen预计将于今年下半年的学术大会上公布该III期临床的详细数据。此外，Bema联合化疗及纳武利尤单抗一线治疗胃癌患者的III期研究也在进行中，再鼎预计将于2H25公布数据。再鼎拥有该产品大中华区开发和商业化的独家授权，公司预计将于2H25递交上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2547066090","title":"再鼎医药宣布贝玛妥珠单抗用于FGFR2b阳性一线胃癌的III期研究主要数据取得阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2547066090","media":"再鼎医药","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547066090?lang=zh_cn&edition=full","pubTime":"2025-06-30 21:35","pubTimestamp":1751290531,"startTime":"0","endTime":"0","summary":"目前在中国尚无专门针对FGFR2b过表达胃癌的获批疗法。贝玛妥珠单抗已获得中国国家药品监督管理局药品审评中心授予的突破性疗法认定，用于治疗FGFR2b阳性胃癌及胃食管结合部癌。一项贝玛妥珠单抗联合化疗及纳武利尤单抗一线治疗胃癌患者的III期研究也正在进行，数据预计在2025年下半年公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630220443a4c6d387&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630220443a4c6d387&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","LU2488822045.USD","BK1161","ZLAB","BK1588","BK1574"],"gpt_icon":0},{"id":"2547509735","title":"再鼎医药盘中异动 早盘快速拉升5.73%报36.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2547509735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547509735?lang=zh_cn&edition=full","pubTime":"2025-06-30 21:30","pubTimestamp":1751290249,"startTime":"0","endTime":"0","summary":"北京时间2025年06月30日21时30分，再鼎医药股票出现波动，股价快速上涨5.73%。截至发稿，该股报36.73美元/股，成交量4.7906万股，换手率0.04%，振幅0.40%。再鼎医药股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Artelo Biosciences, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Artelo Biosciences, Inc.、Klotho Neurosciences, Inc.、Inmune Bio Inc.较为活跃，换手率分别为2005.79%、109.93%、57.73%，振幅较大的相关个股有Rallybio Corporation、Ovid Therapeutics Inc.、Diamedica Therapeutics Inc.，振幅分别为5.44%、4.01%、3.39%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630213049a726423e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630213049a726423e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4585","BK4526","BK4531","BK4588","BK4139","LU2488822045.USD","BK4548"],"gpt_icon":0},{"id":"2546571870","title":"再鼎医药(09688)：欧阳丽妮辞任联席公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2546571870","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546571870?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:50","pubTimestamp":1751014234,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，欧阳丽妮女士已辞任该公司联席公司秘书及授权代表，自2025年6月27日起生效。另一名联席公司秘书Frazor Titus Edmondson III先生将担任公司唯一的公司秘书并获委任为授权代表，自2025年6月27日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","LU2488822045.USD","BK4531","BK1161","BK4526","BK4585","BK4588","ZLAB","BK1588","BK4548","BK1574","BK4139"],"gpt_icon":0},{"id":"2546716338","title":"再鼎医药6月26日成交额为2037.34万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546716338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546716338?lang=zh_cn&edition=full","pubTime":"2025-06-27 15:52","pubTimestamp":1751010723,"startTime":"0","endTime":"0","summary":"美东时间2025年6月26日，再鼎医药成交额为2037.34万美元，成交额较昨日减少27.81%，当日成交量为56.31万股。再鼎医药于2025年6月26日跌2.08%，报36.19美元，该股过去5个交易日跌2.0%，年初至今涨38.18%，过去60日涨0.14%。公司的专利候选药物产品管线包括 ZL-1218  实体瘤、ZL-1310  ES-SCLC 其他 NECs、ZL-6301  实体瘤、ZL6201  实体瘤。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627171914a720850d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627171914a720850d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","LU2488822045.USD","BK4531","BK4526","BK4588","ZLAB","BK4139","BK4585"],"gpt_icon":0},{"id":"2546975958","title":"热门中概股涨跌不一纳斯达克中国金龙指数跌0.29%。小马智行涨约12%金山云、万国数据涨超3%霸王茶姬、亚朵涨超1%京东","url":"https://stock-news.laohu8.com/highlight/detail?id=2546975958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546975958?lang=zh_cn&edition=full","pubTime":"2025-06-27 04:00","pubTimestamp":1750968021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PONY","02015","XPEV","LU0499858602.USD","03896","LU0051755006.USD","BABA","IE0034224299.USD","KC","TCOM","LU0672654166.SGD","LU0502904849.HKD","HXC","09618","09866","03888","ATAT","NIO.SI","LU0039217434.USD","BK1119","09988","EVS.SI","LU1044874839.SGD","LU0791590937.USD","LU0315179316.USD","89618","TTTN","BK4510","JD","LU2039709279.SGD","09901","09868","BK1531","09688","LU1303224171.USD","BEKE","LU1328277881.USD","09698","CHA","LU2328871848.SGD","LU2399975544.HKD","NIO","LI","LU0588545904.SGD","TAL","YMM","ALBmain","ZLAB","EDU","GDS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":-0.0832},{"period":"3month","weight":0.2912},{"period":"6month","weight":0.4379},{"period":"1year","weight":1.0589},{"period":"ytd","weight":0.3341}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0354},{"period":"3month","weight":0.1307},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.1172},{"period":"ytd","weight":0.0585}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":0.014818},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":0.008126},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.375,"avgChangeRate":-0.005296},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018507},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.066935},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.625,"avgChangeRate":0.141461},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016217}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}